Validation of a new blood biomarker for early diagnosis of Parkinson's disease
Evaluation De La Performance Clinique D'un Nouveau Biomarqueur Sanguin Des Phases Précoces De La Maladie De Parkinson
This study is testing a new blood marker to see if it can help doctors spot Parkinson's disease early and tell it apart from similar conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Trial ID | NCT05385315 on ClinicalTrials.gov |
What this trial studies
This study investigates a newly discovered metabolic biomarker that predicts Parkinson's disease (PD) at early stages. The research aims to evaluate how this biomarker evolves in patients with advanced PD and in newly diagnosed patients from different geographical areas. Additionally, the study will assess the biomarker's ability to differentiate between PD and similar conditions like Multiple System Atrophy (MSA). By improving the clinical diagnosis of early PD, this research could lead to better therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates include patients with newly diagnosed Parkinson's disease and those with advanced Parkinson's disease who are already receiving treatment.
Not a fit: Patients with deep brain stimulation or other neurodegenerative diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable blood test for the early diagnosis of Parkinson's disease, potentially leading to earlier interventions.
How similar studies have performed: Other studies have shown promising results with similar metabolic biomarker approaches, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with de novo Parkinson's disease, without dopaminergic treatment * Patients with advanced Parkinson's disease (\> 5years) with dopaminergic treatment * Patients with multiple system atrophy Exclusion Criteria: * Patients with deep brain stimulation * Other neurodegenerative diseases * patients protected by french law (pregnant or lactating women, prisoners, ...)
Where this trial is running
Grenoble
- CHU Grenoble Alpes — Grenoble, France (Recruiting)
Study contacts
- Principal investigator: Elena Moro — University Hospital, Grenoble
- Study coordinator: Florence Fauvelle, PhD
- Email: florence.fauvelle@univ-grenoble-alpes.fr
- Phone: (33)456520600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.